

# Clinical trials of antithrombotics for heart failure in all type of patients

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 anticoagulant

Trial	Treatments	Patients	Trials design and methods
<b>warfarin vs no treatment</b>			
<b>WASH (warfarin) , 2004</b> n=89/99 follow-up: 27 months	warfarin (target INR 2.5) versus no treatment	patients with heart failure and left ventricular systolic dysfunction requiring diuretic therapy with LVEF<=35%	Parallel groups open UK, US
<b>warfarin vs placebo</b>			
<b>HELAS (warfarin vs placebo) , 2006</b> n=38/44 follow-up: 21.9 months	warfarin (target INR of 23) versus placebo	HF due to dilated cardiomyopathy	Parallel groups double blind Europe
<b>Barzizza (warfarin) , 1993</b> n=24/23 follow-up: 6 months	warfarin to maintain INR between 2 and 3 versus placebo	patients with dilated cardiomyopathy and evidence of intraventricular thrombi	NA
<b>warfarin vs aspirin</b>			
<b>WATCH (warfarin vs aspirin) , 2009</b> [NCT00007683] n=540/523 follow-up:	warfarin (target INR 2.5-3.0) versus aspirin 162 mg daily	symptomatic heart failure patients in sinus rhythm with ejection fractions 35% taking angiotensin-converting enzyme inhibitors (unless not tolerated) and diuretics	Parallel groups open
<b>HELAS (warfarin vs aspirin) , 2006</b> n=54/61 follow-up: 21.9 months	warfarin versus aspirin 325mg/d	HF related to ischemic heart disease with LVFE<35%	Parallel groups Double blind Europe

## References

### WASH (warfarin), 2004:

Cleland JG, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, Prentice C, Ford I, Trainer A, Poole-Wilson PA, The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. *Am Heart J* 2004;148:157-64. [15215806] [10.1016/j.ahj.2004.03.010](https://doi.org/10.1016/j.ahj.2004.03.010)

### HELAS (warfarin vs placebo), 2006:

Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. *Eur J Heart Fail* 2006 Jun;8:428-32 [16737850]

### Barzizza (warfarin), 1993:

Barzizza F, Zocchi MT, Magnani L.p, imag Antiplatelet drugs versus warfarin in treatment of intraventricular thrombi *Eur Heart J* 1993;14(suppl):396 (Abstract P2118)

### WATCH (warfarin vs aspirin), 2009:

Massie BM, Krol WF, Ammon SE, Armstrong PW, Cleland JG, Collins JF, Ezekowitz M, Jafri SM, O'Connor CM, Packer M, Schulman KA, Teo K, Warren S, The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail 2004;10:101-12. [15101020]

Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O'Connor CM, Schulman KA, Teo K, Warren SR Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009 Mar 31;119:1616-24 [19289640]

### HELAS (warfarin vs aspirin), 2006:

Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 2006 Jun;8:428-32 [16737850]

## 2 NOAC

Trial	Treatments	Patients	Trials design and methods
<b>rivaroxaban vs placebo</b>			
COMMANDER HF <i>ongoing</i> [NCT01877915] n=5000 follow-up:	Rivaroxaban 2.5 mg versus placebo	Subjects With Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure	

## References

COMMANDER HF, :

## 3 platelet aggregation inhibitors

Trial	Treatments	Patients	Trials design and methods
<b>aspirin vs no treatment</b>			
WASH (aspirin) , 2004 n=91/99 follow-up: 27 months	aspirin 300 mg/day versus no treatment	patients with heart failure and left ventricular systolic dysfunction requiring diuretic therapy with LVEF<=35%	open UK, US
<b>vs placebo</b>			
Barzizza (A+D) , 1993 n=25/23 follow-up: 6 months	aspirin 300mg + dipyridamole 200mg versus placebo	patients with dilated cardiomyopathy and evidence of intraventricular thrombi	NA
<b>aspirin vs placebo</b>			
Barzizza (ASA) , 1993 n=26/23 follow-up: 6 months	aspirin 300mg versus placebo	patients with dilated cardiomyopathy and evidence of intraventricular thrombi	Parallel groups NA
<b>clopidogrel vs aspirin</b>			

continued...

Trial	Treatments	Patients	Trials design and methods
<b>WATCH (clopidogrel vs aspirin) ongoing</b> n=524/523 follow-up:	warfarin (target INR 2.5-3.0) , clopidogrel versus aspirin 162 mg daily	symptomatic heart failure patients in sinus rhythm with ejection fractions 35% taking angiotensin-converting enzyme inhibitors (unless not tolerated) and diuretics	double blind

## References

### WASH (aspirin), 2004:

Cleland JG, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, Prentice C, Ford I, Trainer A, Poole-Wilson PA, The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. *Am Heart J* 2004;148:157-64. [[15215806](#)] [10.1016/j.ahj.2004.03.010](#)

### Barzizza (A+D), 1993:

Barzizza F, Zocchi MT, Magnani L.p, imag Antiplatelet drugs versus warfarin in treatment of intraventricular thrombi *Eur Heart J* 1993;14(suppl):396 (Abstract P2118)

### Barzizza (ASA), 1993:

Barzizza F, Zocchi MT, Magnani L.p, imag Antiplatelet drugs versus warfarin in treatment of intraventricular thrombi *Eur Heart J* 1993;14(suppl):396 (Abstract P2118)

### WATCH (clopidogrel vs aspirin), 0:

Massie BM, Krol WF, Ammon SE, Armstrong PW, Cleland JG, Collins JF, Ezekowitz M, Jafri SM, O'Connor CM, Packer M, Schulman KA, Teo K, Warren S, The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. *J Card Fail* 2004;10:101-12. [[15101020](#)]

Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O'Connor CM, Schulman KA, Teo K, Warren SR Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. *Circulation* 2009 Mar 31;119:1616-24 [[19289640](#)]

3

## 4 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.